Učitavanje...
ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
PURPOSE: The purpose of this study was to explore the frequencies of ALK and ROS1 fusion genes in EGFR-mutant lung adenocarcinoma patients and examine the therapeutic efficacies of EGFR-tyrosine kinase inhibitors (TKIs). MATERIALS AND METHODS: A total of 421 EGFR-mutated patients taking EGFR-TKIs we...
Spremljeno u:
| Izdano u: | Onco Targets Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513887/ https://ncbi.nlm.nih.gov/pubmed/28744144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S133349 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|